TX-FLUENCE
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its ongoing research at Delphy Improvement Centre, an independent institute and expert in food and flowers located in Bleiswijk, the Netherlands, studying how Fluence’s LED lighting solutions impact strawberry production in greenhouses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005389/en/
Traditionally grown in outdoor fields, strawberries are temperature-sensitive crops, restricting growers in the northern hemisphere to limited seasonal production cycles. The research trial aims to examine industry-leading best practices for efficiently growing strawberries in a controlled environment by introducing supplemental lighting.
“Strawberries are particularly sensitive to their environment, so studying the crop in a greenhouse climate enables us to explore supplemental lighting techniques growers can replicate year-round,” said David Hawley, Ph.D., Fluence’s senior scientist. “Teaming up with Delphy’s expert researchers affords us the opportunity to learn more about producing consistent, high-yielding strawberry plants under LED lighting to advance local production capabilities for European markets.”
Greenhouse growers have shown increasing interest in switching from legacy systems such as high-pressure sodium lighting to LED fixtures to analyze how various light spectra affect crop quality and consistency. The study focuses on June-bearing strawberry cultivars—popular among European growers for their sweetness and cost in comparison to ever-bearing varieties—under a variety of Fluence’s PhysioSpec™ spectra offerings.
“In the research trial with Fluence, we’re using our teams’ collective knowledge and exchanging innovative ideas for growing techniques that will ultimately help growers deliver better products to local consumers all year,” said Lisanne Helmus, manager of research in greenhouse horticulture at Delphy. “Growers are searching for optimized lighting strategies and want to understand how their plants will react to artificial light. In this trial with Fluence, we’re inspired to answer their questions and discover new developments in lighting technology that will impact the entire cultivation system.”
Fluence and Delphy are expected to publish trial results later this year. For more information on Fluence, visit www.fluence.science . For more information on Delphy, visit www.delphy.nl/en .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
About Delphy Improvement Centre
Delphy Improvement Centre, located Bleiswijk, the Netherlands, is a recognized research institute that executes cultivation-related trials in all kinds of crops. The experiments are performed in a modern greenhouse complex located in close proximity to their target audience: The growers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005389/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness15.1.2026 13:01:00 CET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program. The collaboration provides Agenus with strategic capital and committed, long-term biologics manufacturing capacity in the United States to support BOT+BAL clinical development, authorized early access pathways, and commercial supply preparation. As part of the collaboration, Agenus has granted Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories. The collaboration, first announced on June 3, 2025, included the following key financial terms: Upfront Consideration: $75 million cash payment to Agenus for transfer of biologics manufac
WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion15.1.2026 13:00:00 CET | Press release
The WHOOP x SR_A collaboration ushers in a new frontier of performance accessories, apparel, and design-driven technology WHOOP, the human performance company, announces a landmark creative partnership with acclaimed designer Samuel Ross MBE, who joins as Global Creative Director, WHOOP x SR_A to lead a multiyear collaboration between the two brands titled PROJECT TERRAIN. The collaboration signals the ongoing evolution of WHOOP from a pioneering wearable technology company into a brand shaping not just the future of personal health but also its intersection with performance fashion and cultural design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115643104/en/ WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion As the first performance design collaboration for WHOOP, the partnership represents a new chapter for the brand. Under Ross’ direction, PROJECT
TNG Digital and EPOS Launch EPOS360 and EPOS360 BlueTap in Malaysia to Help Local SMEs Grow with AI and Unique Payment Capabilities15.1.2026 11:23:00 CET | Press release
EPOS360, an industry-first all-in-one digital and payments solution, launches as a mini-programme within TNG eWallet, enabling Malaysian SMEs to easily access AI-powered growth tools to engage over 25 million TNG eWallet usersTNG Digital introduces EPOS360 BlueTap, Malaysia’s first tap-to-pay experience using TNG eWalletThrough EPOS, Ant International will make significant strides to empower SME digitalisation, leading the charge for its SME inclusion and growth strategy TNG Digital Sdn. Bhd. (“TNG Digital”), the operator of Malaysia’s leading digital financial services and lifestyle app, TNG eWallet, and EPOS, the all-in-one SME transformation platform of Ant International, have jointly announced the launch of EPOS360 in Malaysia, with a suite of AI-powered growth tools and unique payment capabilities to support the digitalisation of Malaysian businesses, particularly SMEs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260
UK CfD AR7 Results Signal New Realities for Offshore Wind Economics Ahead of AR8 — Aegir Insights15.1.2026 10:38:00 CET | Press release
The UK government yesterday published the results of the highly anticipated Contracts for Difference (CfD) Allocation Round 7 (AR7), highlighting both sustained appetite for UK offshore wind and the growing complexity of delivering competitive, bankable bids. The allocation round awarded a record 8.4 GW of offshore wind capacity across eight projects after the government increased the budget during the process. Almost all capacity (8.2 GW) was allocated to fixed-bottom offshore wind, enabling six large-scale projects to move forward and strengthening the UK’s deployment pipeline towards 2030. However, the outcome also revealed a large degree of project concentration, with partial or full ownership of five of the six awarded fixed-bottom projects held by a single developer. In a sector still recovering from cost and delivery risk, AR7 represents a positive outcome and signals an industry beginning to recalibrate under the right support framework. “The AR7 results provide important signa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
